Mind Medicine (MindMed) Inc. (MNMD)
$2.9
-0.08 (-2.68%)
Rating:
Recommendation:
-
| Symbol | MNMD |
|---|---|
| Price | $2.9 |
| Beta | 2.196 |
| Volume Avg. | 0.56M |
| Market Cap | 110.384M |
| Shares () | - |
| 52 Week Range | 2.12-19.95 |
| 1y Target Est | - |
| DCF Unlevered | MNMD DCF -> | |
|---|---|---|
| DCF Levered | MNMD LDCF -> | |
| ROE | -40.15% | Strong Sell |
| ROA | -33.41% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 12.64% | Neutral |
| P/E | -1.60 | Sell |
| P/B | 0.59 | Buy |
Latest MNMD news
About
Download (Excel)Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.